Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

66 results about "Sigma ligands" patented technology

Sigma ligands for neuronal regeneration and functional recovery

InactiveUS20050020483A1Improve functional recoveryEnhance neuronal regenerationBiocideNervous disorderHuntingtons choreaNeuro-degenerative disease
The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptors. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.
Owner:MS SCI CORP

Bis(tetrahydro-indenyl) metallocenes as olefin-polymerization-catalyst

A new class of bridged bis(tetrahydro-indenyl)metallocenes of formula (I),wherein M is Zr or Hf; X are monoanionic sigma ligands; (ZR1i)j is a divalent group bridging the two tetrahydro-indenyl residues; R2 and R3 are halogen, alkyl, cycloalkyl, aryl, alklyaryl or arylalkyl radicals; p is 0-3; i is 1 or 2; j is 1-4; m is 1-2; and n is 0-8. Furthermore, catalysts systems for olefin polymerization containing them are described.
Owner:BASELL POLYOLEFINE GMBH

Process for the preparation of metallocene compounds

A new process is disclosed, particularly simple, convenient and practical, for the direct synthesis of metallocenes of formula (I): (CP)(ZR1m)n(A)rMLpL'q wherein (ZR1m)n is a divalent group bridging Cp and A; Cp is a substituted or unsubstituted cyclopentadieryl group; A is -O-, -S-, -N(R2)-, wherein R2 is hydrogen, alkyl, cycloalkyl aryl, alkylaryl or arylalkyl, or A has the same meaning of Cp; M is a transition metal belonging to group 3, 4, 5, 6 or to the lanthanide or actinide groups; L is a monoanionic sigma ligand, such as alkyl, cycloalkyl, aryl, alkylaryl or arylalkyl, optionally containing Si or Ge; L' is halogen or -OR5, R5 being a hydrocarbon radical; m is 1 or 2; n is 0-4; r is 0 or 1; p is 1-3; q is 0-2. Said process comprises reacting the ligand (Y-Cp)(ZR1m)n(A-Y)r, wherein Y is a suitable leaving group, with at least 1 molar equivalent of ML's in the presence of at least (1+r+p) molar equivalents of LjB or LMgL', wherein B is an alkaline or alkaline-earth metal, s ranges from 3 to 6, and j is 1 or 2.
Owner:MONTELL TECH CO BV

Sigma ligands for neuronal regeneration and functional recovery

The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably SA-4503, or salts, or solvates thereof These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.
Owner:MS SCI CORP

Sigma ligands for neuronal regeneration and functional recovery

The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.
Owner:MS SCI CORP

Sigma ligands for use in the prevention and/or treatment of post-operative pain

InactiveUS20120302568A1Nervous disorderAntipyreticPeripheral neuropathic painHyperesthesia
The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and / or treat acute and chronic pain developed as a consequence of surgery, especially superficial and / or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.
Owner:LAB DEL DR ESTEVE SA

Sigma ligands for neuronal regeneration and functional recovery

InactiveUS20060014753A1Improve functional recoveryEnhance neuronal regenerationBiocideNervous disorderNeuro-degenerative diseaseNeuron
The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by multiple sclerosis. In other methods, the sigma receptor ligands are administered after MS to facilitate functional recovery. The administration of the sigma receptor ligands causes faster functional recovery.
Owner:MS SCI CORP

Solid particulate catalysts comprising bridged metallocenes

InactiveCN102947354AParticulatesSilylene
A solid, particulate catalyst comprising: (i) a complex of Formula (I), wherein M is zirconium or hafnium; each X is a sigma ligand; L is a divalent bridge selected from -R'2C-, -R'2C-CR'2-, -R'2Si-, -R'2Si-SiR'2-, -R'2Ge-, wherein each R' is independently a hydrogen atom, C1-C20-alkyl, tri(C1-C20-alkyl)silyl, C6-C20-aryl, C7-C20-arylalkyl or C7-C20-alkylaryl; each R1 independently is a linear or branched C1-C20 hydrocarbyl radical optionally containing one or more heteroatoms from groups 14-16; T1 and T4, which can be the same or different, are an OR<2>, a SR<2>, CH(R<18>)2, CH2R<18>, aryl or heteroaryl group; each R<2>, which can be the same or different, is a C1-C20 hydrocarbyl radical; each R<18>, which can be the same or different, is a C1-C20 hydrocarbyl radical or two R<18> groups together with the carbon atom to which they are attached may form a cyclic C4-C20 hydrocarbyl group; T2 and T3, which may be the same or different, are a C(R<18>)3 group; W1 and W2, which may be the same or different, are a 5 or 6 membered aryl or heteroaryl ring wherein each atom of said ring is optionally substituted with an R<5> group; each R<5>, which can be the same or different, is a C1-C20 hydrocarbyl radical optionally containing one or more heteroatoms belonging to groups 14-16; and optionally two adjacent R<5> groups taken together can form a further mono or multicyclic ring condensed to W1 or W2, optionally substituted by one or two groups R5; and (ii) a cocatalyst.
Owner:BOREALIS AG

Improved catalyst system for producing polyethylene copolymers in a high temperature solution polymerization process

Catalyst system for producing ethylene copolymers in a high temperature solution process, the catalyst system comprising (i) a metallocene complex of formula (I) wherein M is Hf or Zr X is a sigma ligand, L is a bridge of the formula —SiR82—, wherein each R8 is independently a C1-C20-hydrocarbyl, tri(C1-C20-alkyl)silyl, C6-C20-aryl, C7-C20-arylalkyl or C7-C20-alkylaryl n is 0, 1 or 2 R1 and R1′ are the same or can be different and can be a linear or branched C1-C6-alkyl group, R2 and R2′ are the same or are different and are a CH2—R9 group, with R9 being H or linear or branched C1-C6-alkyl group R5 and R5′ are the same or are different and can be H or a linear or branched C1-C6-alkyl group or a OR group, wherein R is a C1-C6-alkyl group R6 and R6′ are the same or are different and can be H or a C(R10)3 group, with R10 being the same or different and R10 can be H or a linear or branched C1-C6-alkyl group or R5 and R6 and / or R5′ and R6′ taken together form an unsubstituted 4-7 membered ring condensed to the benzene ring of the indenyl moiety, with the proviso that if R5 and R6 as well as R5′ and R6′ taken together form an unsubstituted 5 membered ring condensed to the benzene ring of the indenyl moiety then R2 and R2′ are not a C1-alkyl group; and R7 and R7′ can be the same or are different and can be H or a linear or branched C1-C6-alkyl group (ii) an aluminoxane cocatalyst and (iii) optionally a boron containing cocatalyst
Owner:BOREALIS AG

Sigma ligands for neuronal regeneration and functional recovery

The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferable AGY-94806, or salts or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, Huntington's disease, or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects functional recovery.
Owner:WIELOCH TADEUSZ +2

Transition metal compound, polymerization catalyst using same and process for producing styrenic polymer using said polymerization catalyst

There are disclosed a transition metal compound of the general formula RMXa-1Lb (R is a pi ligand, a fused polycyclic cyclopentadienyl group in which at least one of many-membered rings to which cyclopentadienyl groups are fusedly bonded is a saturated ring, M is a transition metal, X is a sigma ligand, L is a Lewis base, a is the valency of M, and b is 0, 1 or 2); a polymerization catalyst for styrene, etc. comprising the above transition metal, preferably further comprising an oxygen atom containing compound ionic compound or organoboron compound and optionally a Lewis base; and a process for producing a polymer of a compound containing an ethylenically unsaturated double bond or an acetylenic polymer, especially a syndiotactic polystyrene by using the above polymerization catalyst. The catalyst is particularly effective for producing highly syndiotactic polystyrene minimized in residual metals amounts at a low cost in enhanced efficiency.
Owner:IDEMITSU KOSAN CO LTD

Methylene bridged metallocenes as olefin-polymerization-catalyst components

A new class of methylene-bridged metallocenes of formula (I), wherein M is a transition metal of group 3, 4, 5, 6, lanthanide or actinide; X is a monoanionic sigma ligand; R<1 >can be alkyl, cycloalkyl, aryl, alkylaryl or arylalkyl radicals; R<2 >can be halogen, alkyl, cycloalkyl, aryl, alkylaryl or arylalkyl radical; p is 0-3; m is 0-2; and n is 0-4. Furthermore, the corresponding ligands, a new process for their preparation and catalysts systems containing said methylene-bridged metallocenes are described.
Owner:BASELL POLYOLEFINE GMBH

1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof

The invention relates to the use of a group of sigma receptor ligands of formula (I)for the potentiation of the analgesic effect of opioids and opiates and at the same time for decreasing the dependency induced by them.
Owner:LAB DEL DR ESTEVE SA

catalyst

A catalyst in solid particulate form free from an external carrier material comprising(i) a complex of formula (I)whereinM is zirconium or hafnium;each X is a sigma ligand;L is a divalent bridge selected from —R′2C—, —R′2C—CR′2—, —R′2Si—, —R′2Si—SiR′2—, —R′2Ge—, wherein each R′ is independently a hydrogen atom, C1-20-alkyl, tri(C1-20-alkyl)silyl, C6-20-aryl, C7-20-arylalkyl or C7-20-alkylaryl;R2 is a C1-20-hydrocarbyl radical;R2′ is a C1-20-hydrocarbyl radical;R6 is a linear or branched aliphatic C1-20-hydrocarbyl group, SR9 or OR9;R6′ is a linear or branched aliphatic C1-20-hydrocarbyl group, SR9′ or OR9′;with the proviso that neither R6 or R6′ represents a group having a quaternary carbon atom directly attached to the indenyl ring;R9 is a C1-20-hydrocarbyl group;R9′ is a C1-20-hydrocarbyl group;Ar is a C6-12-aryl or C5-12-heteroaryl group optionally carrying one or more substituents R8;Ar′ is a C6-12-aryl or C5-12-heteroaryl group optionally carrying one or more substituents R8′;each R8 is a C1-20-hydrocarbyl group;each R8′ is a C1-20-hydrocarbyl group; andwherein at least two of R2 and R2′; R6 and R6′; or Ar and Ar′ are the same;and (ii) a cocatalyst comprising a compound of a group 13 metal, e.g. Al or boron.
Owner:BOREALIS AG

Catalysts

A racemic complex of formula (I), wherein M is zirconium or hafnium; each X is a sigma ligand; L is a divalent bridge selected from —R′2C—, —R′2C—CR′2, —R′2Si—, —R′2Si—SiR′2—, —R′2Ge—, wherein each R′ is independently a hydrogen atom, C1-20-hydrocarbyl, tri(C1-20-alkyl)silyl, C6-20-aryl, C7-20-arylalkyl or C7-20-alkylaryl; R2 and R2′ are each independently a C1-20 hydrocarbyl radical optionally containing one or more heteroatoms from groups 14-16; R5′ is a C1-20 hydrocarbyl group optionally containing one or more heteroatoms from groups 14-16 and optionally substituted by one or more halo atoms.
Owner:BOREALIS AG

Catalysts

A complex of formula (I) wherein M is zirconium or hafnium; each X independently is a sigma ligand; L is a divalent bridge selected from —R′2C—, —R′2C—CR′2—, —R′2Si—, —R′2Si—SiR′2—, —R′2Ge—, wherein each R′ is independently a hydrogen atom or a C1-C20-hydrocarbyl group optionally containing one or more silicon atoms or heteroatoms of Group 14-16 of the periodic table or fluorine atoms, and optionally two R′ groups taken together can form a ring; R2 and R2′ are each independently a C1-C20 hydrocarbyl group, —OC1-hydrocarbyl group or —SC1-20 hydrocarbyl group; R5 is a —OC1-20 hydrocarbyl group or —SC1-20 hydrocarbyl group, said R5 group being optionally substituted by one or more halo groups; R5′ is hydrogen or a C1-20 hydrocarbyl group; —OC1-20 hydrocarbyl group or —SC1-20 hydrocarbyl group; said C1-20 hydrocarbyl group being optionally substituted by one or more halo groups; R6 and R6′ are each independently a C1-20 hydrocarbyl group; —C1-20 hydrocarbyl group or —SC1-20 hydrocarbyl group; each R1 and R1′ are independently —CH2Rx wherein Rx are each independently H, or a C1-20 hydrocarbyl group, optionally containing heteroatoms.
Owner:BOREALIS AG

Method for preparing metallocene compounds

A new process is disclosed, particularly simple, convenient and practical, for the direct synthesis of metallocenes of formula (I): (CP)(ZR1m)n(A)rMLpL'q wherein (ZR1m)n is a divalent group bridging Cp and A; Cp is a substituted or unsubstituted cyclopentadieryl group; A is -O-, -S-, -N(R2)-, wherein R2 is hydrogen, alkyl, cycloalkyl aryl, alkylaryl or arylalkyl, or A has the same meaning of Cp; M is a transition metal belonging to group 3, 4, 5, 6 or to the lanthanide or actinide groups; L is a monoanionic sigma ligand, such as alkyl, cycloalkyl, aryl, alkylaryl or arylalkyl, optionally containing Si or Ge; L' is halogen or -OR5, R5 being a hydrocarbon radical; m is 1 or 2; n is 0-4; r is 0 or 1; p is 1-3; q is 0-2. Said process comprises reacting the ligand (Y-Cp)(ZR1m)n(A-Y)r, wherein Y is a suitable leaving group, with at least 1 molar equivalent of ML's in the presence of at least (1+r+p) molar equivalents of LjB or LMgL', wherein B is an alkaline or alkaline-earth metal, s ranges from 3 to 6, and j is 1 or 2.
Owner:MONTELL TECH CO BV

Process for the preparation of a solid metallocene catalyst system and its use in polymerisation of olefins

A process for the preparation of a solid olefin polymerisation catalyst system, comprising an organometallic compound of a transition metal of Group 3 to 10 of the Periodic Table (IUPAC 2007) in the form of solid particles comprising the steps of I) generating an emulsion by dispersing a liquid clathrate in a solvent (S) wherein (i) the solvent (S) constitutes the continuous phase of the emulsion and comprises a nonreactive fluorinated synthetic oil having a viscosity at 20 DEG C according to ASTM D445 of at least 10 cSt up to 2000 cSt, (ii) the liquid clathrate constitutes in form of droplets the dispersed phase of the emulsion, II) solidifying said dispersed phase to convert said droplets to solid particles and III) optionally recovering said particles to obtain said catalyst system, wherein the liquid clathrate comprises (a) a lattice being the reaction product of a1); a transition metal compound of formula (I) LmRnTXq wherein T is a transition metal of anyone of the groups 3 to 10 of the periodic table (IUPAC2007), preferably a transition metal of anyone of the groups 4 to 6 of the periodic table (IUPAC2007), more preferably titanium (Ti), zirconium (Zr) or hafnium (Hf), i.e. zirconium (Zr) or hafnium (Hf), each X is independently a monovalent sigma-ligand, each L is independently an organic ligand which coordinates to the transition metal (T), R is a bridging group linking said organic ligands (L), m is 2 or 3, preferably 2, n is 0, 1 or 2, preferably 1, q is 1, 2 or 3, preferably 2, m+q is equal to the valency of the transition metal (T), a2) a cocatalyst comprising aluminoxane a3) a compound being effective to form the lattice with the transition metal compound and / or the aluminoxaneand b) a hydrocarbon solvent (HS).
Owner:北欧化工公司

Catalyst system for producing polyethylene copolymers in a high temperature solution polymerization process

Catalyst system for producing ethylene copolymers in a high temperature solution process, the catalyst system comprising (i) a metallocene complex of formula (I) wherein M is Hf or Zr X is a sigma ligand, L is a bridge of the formula —SiR82—, wherein each R8 is independently a C1-C20-hydrocarbyl, tri(C1-C20-alkyl)silyl, C6-C20-aryl, C7-C20-arylalkyl or C7-C20-alkylaryl n is 0, 1 or 2 R1 and R1′ are the same or can be different and can be a linear or branched C1-C6-alkyl group, R2 and R2′ are the same or are different and are a CH2—R9 group, with R9 being H or linear or branched C1-C6-alkyl group R5 and R5′ are the same or are different and can be H or a linear or branched C1-C6-alkyl group or a OR group, wherein R is a C1-C6-alkyl group R6 and R6′ are the same or are different and can be H or a C(R10)3 group, with R10 being the same or different and R10 can be H or a linear or branched C1-C6-alkyl group or R5 and R6 and / or R5′ and R6′ taken together form an unsubstituted 4-7 membered ring condensed to the benzene ring of the indenyl moiety, with the proviso that if R5 and R6 as well as R5′ and R6′ taken together form an unsubstituted 5 membered ring condensed to the benzene ring of the indenyl moiety then R2 and R2′ are not a C1-alkyl group; and R7 and R7′ can be the same or are different and can be H or a linear or branched C1-C6-alkyl group (ii) an aluminoxane cocatalyst and (iii) optionally a boron containing cocatalyst.
Owner:BOREALIS AG

Catalyst system for producing polyethylene copolymers in a high temperature solution polymerization process

Catalyst system for producing ethylene copolymers in a high temperature solution process, the catalyst system comprising (i) a metallocene complex of formula (I) wherein M is Hf X is a sigma ligand, L is a bridge of the formula —SiR82—, wherein each R8 is independently a C1-C20-hydrocarbyl, tri(C1-C20-alkyl)silyl, C6-C20-aryl, C7-C20-arylalkyl or C7-C20-alkylaryl n is 0, 1 or 2 R1 and R1′ are the same or can be different and can be a linear or branched C1-C6-alkyl group, R2 and R2′ are the same or are different and are a CH2—R9 group, with R9 being H or linear or branched C1-C6-alkyl group R5 and R5′ are the same or are different and can be H or a linear or branched C1-C6-alkyl group or a OR group, wherein R is a C1-C6-alkyl group R6 and R6′ are the same or are different and can be H or a C(R10)3 group, with R10 being the same or different and R10 can be H or a linear or branched C1-C6-alkyl group or R5 and R6 and / or R5′ and R6′ taken together form an unsubstituted 4-7 membered ring condensed to the benzene ring of the indenyl moiety, and R7 and R7′ can be the same or are different and can be H or a linear or branched C1-C6-alkyl group (ii) an aluminoxane cocatalyst and / or (iii) a boron containing cocatalyst and (iv) optionally an aluminum alkyl compound.
Owner:BOREALIS AG

Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof

The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and / or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (I) for use in potentiating the analgesic effect of an opioid or opiate and / or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and / or treatment of pain developed as a consequence of surgery.
Owner:LAB DEL DR ESTEVE SA

Sigma ligands for neuronal regeneration and functional recovery

The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably SA-4503, or salts, or solvates thereof These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.
Owner:MS SCI CORP

New catalyst system for producing polyethylene copolymers in a high temperature solution polymerization process

Catalyst system for producing ethylene copolymers in a high temperature solution process, the catalyst system comprising (i) a metallocene complex of formula (I), M is Hf or a mixture with Zr, provided that more than 50% by moles of the complex of Formula I has M=Hf, X is a sigma ligand, R are the same or different from each other and can be saturated linear or branched C1-C10 alkyl, C5-C10 aryl, C6-C20 alkylaryl or C6-C20 arylalkyl groups, which can optionally contain up to 2 heteroatoms or silicon atoms, R1 is a C6-C20-aryl, which can be unsubstituted or substituted by one or up to 5 linear or branched C1-C10 alkyl group(s), R2 is a saturated linear or cyclic C3-C20 alkyl group or a branched CR3R4R5 group, wherein R3 is hydrogen or an C1-C20 alkyl group and R4 and R5 are the same or are different and can be an C1-C20 alkyl group and (ii) a boron containing cocatalyst
Owner:BOREALIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products